DRMA
Dermata Therapeutics, Inc.
$1.18
-3.28%
$4.7M
No data for this timeframe.
Vol
Market Cap$4.7M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$1.00
Inst. Activity1 buys / 0 sells
Insider Activity1B / 0S
Insider Net $$1.3K
SEC Reports1
Recent Activity
May 13, 2026
earnings_calendar
DRMA Q1 2026 Earnings Scheduled — 2026-05-13
Feb 26, 2026
SEC
Mary Fisher resigned from Dermata Therapeutics' Board of Directors effective March 31, 2026, reducing the board size fro
8-K — Impact 3/10
Feb 17, 2026
Insider
Bedoya-Toro Munera Maria E bought 1,000 shares
SVP, Regulatory Affairs @ $1.27 ($1.3K)
Inst.
BANK OF AMERICA CORP — DOUBLED
3,457 shares ($8.0K)
Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$4.00 (Aug 2025)
Current $1.18
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 21, 2025 | Maxim Group | MAINTAIN | Buy → Buy |
| May 21, 2025 | Maxim Group | MAINTAIN | Buy → Buy |
| Aug 21, 2024 | Maxim Group | MAINTAIN | Buy → Buy |
| Mar 23, 2023 | Maxim Group | MAINTAIN | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.55 ▲ +3.5% | $-0.55 — $-0.55 | 67% YoY | 1 |
| Next Q | $-0.63 ▼ -3.3% | $-0.63 — $-0.63 | 62% YoY | 1 |
| Current FY | $-2.21 | $-2.21 — $-2.21 | 73% YoY | 1 |
| Next FY | $-1.52 ▼ -2.0% | $-1.52 — $-1.52 | 31% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| CITIGROUP INC | $1.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 17, 2026 | Bedoya-Toro Munera | BUY | $1.3K |
1 institutional holders with $1.00 total value (1 shares) as of 2026-Q1. Top holders: CITIGROUP.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | CITIGROUP INC | 1 | $1.00 | 100.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4 | 3,457 | +86325.0% | $8.0K | 2025-Q4 |
1 unique insiders with 1 transactions. Net insider value: $1.3K ($1.3K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | Bedoya-Toro Munera Maria E | SVP, Regulatory Affairs | BUY | 1,000 | $1.27 | $1.3K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Aug 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$4.00 mean target (Aug 2025)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $1.18 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.55 | $-0.55 | $-0.55 | 66.9% | +3.5% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.63 | $-0.63 | $-0.63 | 61.8% | -3.3% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-2.21 | $-2.21 | $-2.21 | 72.9% | -0.5% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-1.52 | $-1.52 | $-1.52 | 31.2% | -2.0% | 0↑ 1↓ | $0.0B | 650.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.550 | |
| 7d ago | $-0.570 | +0.020 |
| 30d ago | $-0.570 | +0.020 |
| 60d ago | $-0.840 | +0.290 |
| 90d ago | $-0.840 | +0.290 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 21, 2025 | Maxim Group | MAINTAIN | Buy | Buy |
| May 21, 2025 | Maxim Group | MAINTAIN | Buy | Buy |
| Aug 21, 2024 | Maxim Group | MAINTAIN | Buy | Buy |
| Mar 23, 2023 | Maxim Group | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
DRMA Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings_calendar
DRMA Q1 2026 Earnings Scheduled — 2026-05-12
Mar 17, 2026
earnings_calendar
DRMA Q4 2025 Earnings After Market Close — 2026-03-17